Altshuler Shaham’s Amicus Therapeutics FOLD Stock Holding History

Altshuler Shaham’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,181	Closed	-$26.6K	–	414
2022 Q4	$26.6K	Sell	2,181 -140	-6%	-$1.58K	﹤0.01%	326
2022 Q3	$24K	Buy	+2,321	New	+$25.9K	﹤0.01%	368
2021 Q1	–	Sell	-1,574	Closed	-$36K	–	489
2020 Q4	$36K	Buy	+1,574	New	+$32.2K	﹤0.01%	323
2020 Q1	–	Sell	-1,600	Closed	-$15K	–	509
2019 Q4	$15K	Buy	+1,600	New	+$14.6K	﹤0.01%	286

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Altshuler Shaham's FOLD Position: Q1 2023 in Review

Altshuler Shaham sold out of Amicus Therapeutics (FOLD) in Q1 2023, closing a stake of 2,181 shares — an estimated $26.6K sold.

Altshuler Shaham first reported a position in FOLD in Q4 2019 and held it in 4 quarters. The position peaked at $36K in Q4 2020. 226 funds tracked by Wall St. Rank hold FOLD as of Q1 2023.

Altshuler Shaham reported no remaining Amicus Therapeutics position as of Q1 2023 after selling out during the quarter.
Altshuler Shaham sold 2,181 Amicus Therapeutics shares in Q1 2023, an estimated $26.6K.
Altshuler Shaham first reported a position in Amicus Therapeutics in Q4 2019 and held it in 4 quarters.
Altshuler Shaham's Amicus Therapeutics position peaked at $36K in Q4 2020.
226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2023.

Based on Altshuler Shaham's 13F filing for Q1 2023, filed 9 May 2023.